Cargando…
Ketorolac tromethamine alleviates IL-1β-induced chondrocyte injury by inhibiting COX-2 expression
Osteoarthritis (OA) is one of the most frequently diagnosed chronic diseases, and its prevalence is rising as life expectancy increases. The present study was designed to investigate the role of ketorolac tromethamine (KT) in OA by establishing an in vitro model in ATDC5 cells. The OA model was esta...
Autores principales: | Liu, Chang, Chen, Yizhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992376/ https://www.ncbi.nlm.nih.gov/pubmed/35411209 http://dx.doi.org/10.3892/etm.2022.11267 |
Ejemplares similares
-
Ocular pharmacokinetics of 0.45% ketorolac tromethamine
por: Attar, Mayssa, et al.
Publicado: (2010) -
Entrapment of Ketorolac Tromethamine in Polymeric Vehicle for Controlled Drug Delivery
por: Paliwal, S. K., et al.
Publicado: (2009) -
Optimization of In-vitro Permeation Pattern of Ketorolac Tromethamine Transdermal Patches
por: Kumar De, Pintu, et al.
Publicado: (2011) -
Suprachoroidal injection of ketorolac tromethamine does not cause retinal damage☆
por: Liu, Sumeng, et al.
Publicado: (2012) -
Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: a preliminary study
por: Avila-Vazquez, Medardo, et al.
Publicado: (2004)